Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/9740
|
| Title: | CAPE suppresses migration and invasion of prostate cancer cells via activation of non-canonical Wnt signaling |
| Authors: | Tseng, JC;Lin, CY;Su, LC;Fu, HH;Yang, SD;Chuu, CP |
| Contributors: | Institute of Cellular and Systems Medicine |
| Abstract: | Prostate cancer (PCa) was the fifth most common cancer overall in the world. More than 80% of patients died from PCa developed bone metastases. Caffeic acid phenethyl ester (CAPE) is a main bioactive component of honeybee hive propolis. Transwell and wound healing assays demonstrated that CAPE treatment suppressed the migration and invasion of PC-3 and DU-145 PCa cells. Gelatin zymography and Western blotting indicated that CAPE treatment reduced the abundance and activity of MMP-9 and MMP-2. Analysis using Micro-Western Array (MWA), a high-throughput antibody-based proteomics platform with 264 antibodies detecting signaling proteins involved in important pathways indicated that CAPE treatment induced receptor tyrosine kinase-like orphan receptor 2 (ROR2) in non-canonical Wnt signaling pathway but suppressed abundance of beta-catenin, NF-kappaB activity, PI3K-Akt signaling, and epithelial-mesenchymal transition (EMT). Overexpression or knockdown of ROR2 suppressed or enhanced cell migration of PC-3 cells, respectively. TCF-LEF promoter binding assay revealed that CAPE treatment reduced canonical Wnt signaling. Intraperitoneal injection of CAPE reduced the metastasis of PC-3 xenografts in tail vein injection nude mice model. Immunohistochemical staining demonstrated that CAPE treatment increased abundance of ROR2 and Wnt5a but decreased protein expression of Ki67, Frizzle 4, NF-kappaB p65, MMP-9, Snail, beta-catenin, and phosphorylation of IkappaBalpha. Clinical evidences suggested that genes affected by CAPE treatment (CTNNB1, RELA, FZD5, DVL3, MAPK9, SNAl1, ROR2, SMAD4, NFKBIA, DUSP6, and PLCB3) correlate with the aggressiveness of PCa. Our study suggested that CAPE may be a potential therapeutic agent for patients with advanced PCa. |
| Date: | 2016-06 |
| Relation: | Oncotarget. 2016 Jun;7(25):38010-38024. |
| Link to: | http://dx.doi.org/10.18632/oncotarget.9380 |
| Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:000378229100048 |
| Cited Times(Scopus): | http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84978148983 |
| Appears in Collections: | [褚志斌] 期刊論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| PUB27191743.pdf | | 10651Kb | Adobe PDF | 490 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
